Allogeneic CD19-directed chimeric antigen receptor-modified T cells (The Affiliated Hospital of the Chinese Academy of Military Medical Sciences)

N/A

Report date: 2023/01/07 17:46:04

Base Information

Drug NameAllogeneic CD19-directed chimeric antigen receptor-modified T cells (The Affiliated Hospital of the Chinese Academy of Military Medical Sciences)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe Affiliated Hospital Of The Chinese Academy Of Military Medical Science
China Registration ClassN/A

Develop Information

Active CompaniesThe Affiliated Hospital Of The Chinese Academy Of Military Medical Science
Inactive CompaniesN/A
Active IndicationsLeukemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A